Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cardi-Braun is a crystalloid cardioplegic solution developed for myocardial protection during major cardiac surgery involving extracorporeal circulation. Developed by B. Braun in collaboration with Hospital Clinico San Carlos, it is designed to induce rapid and reversible diastolic cardiac arrest (asystole). The solution's mechanism of action relies on a high concentration of potassium ions, which depolarizes the myocardial cell membrane and prevents the generation of action potentials. In addition to electrolytes, Cardi-Braun contains buffering agents like histidine and osmotic agents like mannitol to mitigate intracellular acidosis and cellular edema, thereby protecting the heart from ischemia-reperfusion injury during the surgical procedure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cardi-Braun.